Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
Status:
Not yet recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
Radiotherapy is a mainstay of treatment in head and neck cancer and breast cancer treatment,
typically following surgery and/or chemotherapy. Radiation dermatitis, which involves
redness, dryness, and/or peeling of the skin, occurs in up to 95% of patients receiving
radiation therapy. There is currently no standard therapy for this treatment-related adverse
effect. The aim of this study is to investigate the safety and tolerability (Phase I) and
preliminary efficacy (Phase II) of prophylactic esomeprazole cream ( termed "Dermaprazole")
in patients who require radiation for either breast cancer in the postmastectomy setting or
head and neck cancer in the definitive or adjuvant setting.